Compliance Guide

FDA 21 CFR Part 11 Penetration Testing Requirements and How Sprocket Security Satisfies Them

FDA 21 CFR Part 11 requires healthcare organizations to protect the integrity and authenticity of electronic records and signatures used in regulated activities.

Request A FDA 21 CFR Part 11 Scoped Assessment

21 CFR Part 11 Subpart B — §11.10

Controls for closed systems — the primary technical safeguard requirements that penetration testing directly validates

Ongoing (risk-based)

FDA expects computer system validation (CSV) activities to include periodic security assessments commensurate with system risk and change activity

71%

of life sciences web application and validated system engagements uncover a critical or high-severity finding on first test

The Requirement

What FDA 21 CFR Part 11 Actually Requires

FDA 21 CFR Part 11 doesn't use the phrase "penetration testing" — but the regulation's technical safeguard requirements, combined with FDA's Computer Software Assurance (CSA) guidance and inspection expectations, make clear that adversarial validation of system security is an expected component of any mature Part 11 compliance program.

REQUIREMENT	WHAT IT MEANS IN PRACTICE	HOW SPROCKET SATISFIES THE REQUIREMENT
§11.10(d) - Access controls limiting system use to authorized individuals	Systems must enforce least-privilege access, ensuring only authorized users can use the system or device to access electronic records.	Sprocket tests whether those access controls can be bypassed through privilege escalation, insecure direct object reference, or session manipulation.
§11.10(e) - Audit trails	Audit logs must be computer-generated, time-stamped, and protected against modification — creating an unalterable record of operator actions on regulated data.	Sprocket tests whether audit logs can be altered, suppressed, or bypassed via direct database access or application-layer manipulation — validating that your audit trail evidence will hold up under FDA scrutiny.
§11.10(f) - Operational system checks	Systems must enforce permissible sequencing of steps and events — preventing actions from being performed out of order or outside of authorized workflows.	Sprocket identifies logic flaws that allow sequencing rules and permitting controls to be circumvented — confirming that systems enforce the operational boundaries Part 11 requires.
§11.10(g) - Authority checks	Systems must verify the identity and authority of individuals signing or accessing records — ensuring that only authorized individuals can execute regulated operations or apply electronic signatures.	Sprocket directly challenges whether authority enforcement can be defeated.
§11.10(h) - Device checks	Systems must include input validity checks to determine whether input and instructions are accurate, complete, and within the established limits.	Sprocket's application testing covers injection vulnerabilities and input validation failures that bypass device-level controls — the attack surface §11.10(h) is designed to close.
§11.30 - Controls for open systems	Organizations using open systems to create, modify, or transmit electronic records must employ additional controls — including encryption and digital signatures — to ensure record authenticity and confidentiality.	For cloud-hosted and SaaS environments, Sprocket validates whether encryption, authentication, and boundary controls hold under adversarial conditions.

CONSEQUENCE OF NON-COMPLIANCE

FDA enforcement for Part 11 failures has escalated significantly as the agency's data integrity focus has intensified. A control failure identified by an FDA investigator — rather than discovered and remediated internally — carries consequences that extend well beyond the immediate finding. Form 483 observations citing inadequate electronic record controls trigger mandatory CAPA commitments with defined remediation timelines. Unresolved observations or repeat findings escalate to Warning Letters, which are publicly posted and signal to the agency that the organization's quality systems warrant closer scrutiny. For drug manufacturers and device companies, a Warning Letter tied to data integrity or system security can result in product holds, import alerts, or consent decrees — consequences that affect revenue, supply chain, and regulatory standing across the entire product portfolio, not just the system where the failure originated.

Why Continuous Testing

Benefits Of Continuous Penetration Testing For FDA 21 CFR Part 11 Compliance

Always-current evidence for FDA inspections.

FDA Form 483 observations and Warning Letters increasingly cite inadequate system security controls. Sprocket's continuous model means you're never presenting stale evidence to an investigator.

Validates controls across the full system lifecycle.

Part 11 compliance must survive patches, configuration changes, vendor updates, and integrations. Continuous testing catches control degradation before it becomes a finding.

Supports CAPA requirements.

Identifies a control failure, the finding, severity, and remediation evidence, documented in a format that maps directly to corrective and preventive action workflows — streamlining your response process.

Reduces inspection risk.

Organizations with documented, ongoing security testing programs demonstrate the kind of proactive quality culture FDA inspectors are looking for — reducing the likelihood of observations escalating to Warning Letters.

Covers validated and non-validated systems.

Part 11 risk doesn't stop at your validated system boundary. Test the infrastructure, applications, and integrations your validated systems depend on — so a weakness outside the validation scope can't become a path to your regulated data.

What we find

Common FDA 21 CFR Part 11 Findings Sprocket Surfaces

critical

Audit trail bypass via direct database access

An attacker or insider with database-level access can modify or delete electronic records without triggering the application-layer audit trail, rendering the organization's Part 11 audit log evidence unreliable. In an FDA inspection, a compromised audit trail is one of the most serious findings possible and can result in data integrity challenges affecting product release decisions and regulatory submissions.

high

Broken access controls on regulated records

Privilege escalation or insecure direct object reference vulnerabilities allow unauthorized users to access, modify, or export electronic records that should be restricted by role. A finding of this type directly undermines the §11.10(d) and §11.10(g) authority check requirements and can trigger FDA observations about the integrity of records supporting submissions, batch releases, or clinical trial data.

FAQ

FDA 21 CFR Part 11 Penetration Testing — Frequently Asked Questions

Does FDA 21 CFR Part 11 explicitly require penetration testing?

Not by name — but §11.10 requires technical safeguards that protect electronic records and limit system access to authorized individuals. FDA's Computer Software Assurance (CSA) guidance and the agency's increasing focus on data integrity in inspections make clear that organizations are expected to validate those safeguards through adversarial testing, not just documentation.

Does Part 11 apply to cloud-hosted systems and SaaS platforms we use for regulated activities?

Yes. Part 11 applies to electronic records regardless of where they're hosted. For cloud and SaaS environments, the §11.30 open system requirements apply, and organizations remain responsible for ensuring that vendor-managed systems meet Part 11 technical controls. Sprocket tests these environments as part of a complete regulated system boundary assessment.

How does Sprocket's testing fit into Computer Software Assurance (CSA)?

FDA's CSA guidance shifts the focus from documentation volume to outcome-based evidence that software performs as intended. Sprocket's risk-based, continuous testing model directly aligns to that philosophy — producing evidence that controls work under adversarial conditions, not just that they've been documented as implemented.

How often should Part 11-regulated systems be penetration tested?

FDA expects security assessments to be commensurate with risk and change activity. A validated system that undergoes frequent updates or integrations warrants more frequent testing. Sprocket's continuous model addresses this by removing the manual scheduling burden — your systems stay covered as they evolve.

Can Sprocket findings be used to support CAPA documentation?

Yes. Sprocket's reports include structured finding descriptions, severity ratings, affected controls, and remediation guidance in a format that maps directly into CAPA workflows. Retest reports provide documented evidence of remediation — which is exactly what FDA expects to see when reviewing a CAPA response to a data integrity or system security observation.

What happens if a Part 11 control failure is identified during an FDA inspection?

A control failure identified by an FDA investigator — rather than discovered and remediated internally — significantly increases regulatory exposure. Form 483 observations citing data integrity or system security control failures can escalate to Warning Letters, consent decrees, or import alerts. Proactive penetration testing is the mechanism for finding and fixing those failures before an investigator does.

Other Frameworks Sprocket Supports

OTHER FRAMEWORKS SPROCKET SECURITY SUPPORTS

Our Cookie Policy

Manage Cookies

Use cases

Top Blog Posts